|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| HIV Infections | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Acquired Immunodeficiency Syndrome | |||||
| Communicable Diseases | |||||
| Infection | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunologic Deficiency Syndromes | |||||
| Lentivirus Infections | |||||
| Retroviridae Infections | |||||
| RNA Virus Infections | |||||
| Sexually Transmitted Diseases | |||||
| Sexually Transmitted Diseases, Viral | |||||
| Slow Virus Diseases | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Zidovudine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-HIV Agents | |||||
| Anti-Infective Agents | |||||
| Anti-Retroviral Agents | |||||
| Antimetabolites | |||||
| Antiviral Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Nucleic Acid Synthesis Inhibitors | |||||
| Pharmacologic Actions | |||||
| Reverse Transcriptase Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Glaxo Wellcome | |||||